United Therapeutics (NASDAQ:UTHR) Director Nilda Mesa Sells 258 Shares

United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa sold 258 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total value of $150,137.94. Following the sale, the director owned 5,028 shares in the company, valued at approximately $2,925,944.04. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $579.54 on Thursday. The company has a market cap of $24.60 billion, a P/E ratio of 21.39, a PEG ratio of 1.84 and a beta of 0.60. United Therapeutics Corporation has a one year low of $272.12 and a one year high of $609.35. The business’s 50-day simple moving average is $554.96 and its 200 day simple moving average is $505.54.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.63 earnings per share. Analysts predict that United Therapeutics Corporation will post 27.64 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on UTHR shares. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. UBS Group raised their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research note on Thursday, May 7th. HC Wainwright raised their price objective on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Finally, TD Cowen raised their price objective on United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Arjuna Capital grew its position in shares of United Therapeutics by 2.8% in the 1st quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock worth $393,000 after acquiring an additional 18 shares in the last quarter. Clearstead Advisors LLC grew its position in shares of United Therapeutics by 8.9% in the 3rd quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 23 shares in the last quarter. Sage Rhino Capital LLC grew its position in shares of United Therapeutics by 5.1% in the 1st quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC grew its position in shares of United Therapeutics by 5.4% in the 1st quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after acquiring an additional 24 shares in the last quarter. Finally, Meeder Advisory Services Inc. grew its position in shares of United Therapeutics by 4.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after acquiring an additional 26 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.